Ziconotide for treatment of severe chronic pain (Q37736046)

22 August 2017

Ziconotide for treatment of severe chronic pain (English)

1 reference

22 August 2017

0 references

Rainer Freynhagen

3

0 references

Jörn Lötsch

object named as

Jörn Lötsch

series ordinal

2

0 references

author name string

Achim Schmidtko

series ordinal

1

1 reference

PubMed ID

20413151

22 August 2017

Gerd Geisslinger

series ordinal

4

1 reference

PubMed ID

20413151

22 August 2017

language of work or name

English

0 references

publication date

21 April 2010

1 reference

22 August 2017

1 reference

22 August 2017

375

1 reference

22 August 2017

9725

1 reference

22 August 2017

1569-1577

1 reference

22 August 2017

Update in pain medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

1 reference

7 January 2021

Treatment of neuropathic pain: an overview of recent guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Future directions for intrathecal pain management: a review and update from the interdisciplinary polyanalgesic consensus conference 2007.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Polyanalgesic consensus conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Conus peptides: biodiversity-based discovery and exogenomics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Peptide neurotoxins from fish-hunting cone snails

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Diversity of the neurotoxic Conus peptides: a model for concerted pharmacological discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Ziconotide: neuronal calcium channel blocker for treating severe chronic pain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-conotoxin from Conus magus venom

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Antagonists of neuronal calcium channels: structure, function, and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Targeting N-type and T-type calcium channels for the treatment of pain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Localization and targeting of voltage-dependent ion channels in mammalian central neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (omega-conopeptide MVIIC)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

No NO, no pain? The role of nitric oxide and cGMP in spinal pain processing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

omega-Conotoxin inhibition of excitatory synaptic transmission evoked by dorsal root stimulation in rat superficial dorsal horn.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Central sensitization and LTP: do pain and memory share similar mechanisms?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Localization of N-type Ca2+ channels in the rat spinal cord following chronic constrictive nerve injury.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Plastic change of N-type Ca channel expression after preconditioning is responsible for prostaglandin E2-induced long-lasting allodynia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Impaired long-term memory and long-term potentiation in N-type Ca2+ channel-deficient mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Mechanisms of analgesia by gabapentin and pregabalin--calcium channel alpha2-delta [Cavalpha2-delta] ligands

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Pharmacotherapeutic potential of omega-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conus magus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Targeting chronic and neuropathic pain: the N-type calcium channel comes of age.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Long-term intrathecal ziconotide for chronic pain: an open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Bioavailability of Ziconotide in brain: influx from blood, stability, and diffusion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Ziconotide--a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain--a short review.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Ziconotide: an update and review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Intrathecal ziconotide for refractory chronic pain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Intrathecal ziconotide for neuropathic pain: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Intrathecal ziconotide for complex regional pain syndrome: seven case reports

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

An effective treatment of severe complex regional pain syndrome type 1 in a child using high doses of intrathecal ziconotide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: first demonstration of N-channel function in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Targeting Ca2+ channels to treat pain: T-type versus N-type.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Cell-specific alternative splicing increases calcium channel current density in the pain pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Determinants of inhibition of transiently expressed voltage-gated calcium channels by omega-conotoxins GVIA and MVIIA.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Synthesis of a series of 4-benzyloxyaniline analogues as neuronal N-type calcium channel blockers with improved anticonvulsant and analgesic properties

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Structure-activity study and analgesic efficacy of amino acid derivatives as N-type calcium channel blockers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

L-Cysteine based N-type calcium channel blockers: structure-activity relationships of the C-terminal lipophilic moiety, and oral analgesic efficacy in rat pain models

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Discovery, structure-activity relationship study, and oral analgesic efficacy of cyproheptadine derivatives possessing N-type calcium channel inhibitory activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Structure-activity relationship study of 1,4-dihydropyridine derivatives blocking N-type calcium channels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Analgesic activity of ZC88, a novel N-type voltage-dependent calcium channel blocker, and its modulation of morphine analgesia, tolerance and dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Suppression of formalin-induced nociception by cilnidipine, a voltage-dependent calcium channel blocker

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

Scaffold-based design and synthesis of potent N-type calcium channel blockers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960354-6

7 January 2021

10.1016/S0140-6736(10)60354-6

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20413151